Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for comorbid PTSD and MDD in veterans
NCT04032301Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Sep 2019
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketamine in post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) (2 arms), sponsored by University of Minnesota. Primary endpoints: Montgomery-Asberg Depression Rating Scale at 2 months and PTSD Symptom Scale-Interview for DSM-5 at 2 months. Started Sep 2019; status: completed.
02
Drugs
ketamine
03
Conditions
post-traumatic stress disorder (PTSD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04032301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032301.